Ocugen Inc (OCGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ocugen Inc (OCGN) has a cash flow conversion efficiency ratio of -3.656x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.92 Million) by net assets ($3.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ocugen Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Ocugen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OCGN total liabilities for a breakdown of total debt and financial obligations.
Ocugen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocugen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sygnity SA
WAR:SGN
|
0.071x |
|
Magnum Bhd
KLSE:3859
|
0.025x |
|
Top Gum Industries Ltd
TA:TPGM
|
0.020x |
|
Gemtek Technology Co Ltd
TW:4906
|
0.095x |
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
N/A |
|
Cosmo Chem
KO:005420
|
0.054x |
|
Banco de Valores SA
BA:VALO
|
1.856x |
|
Shaanxi Jinye Science Technology and Education Group Co Ltd
SHE:000812
|
0.148x |
Annual Cash Flow Conversion Efficiency for Ocugen Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Ocugen Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Ocugen Inc (OCGN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $29.63 Million | $-42.14 Million | -1.422x | +7.03% |
| 2023-12-31 | $40.56 Million | $-62.05 Million | -1.530x | -88.38% |
| 2022-12-31 | $73.98 Million | $-60.08 Million | -0.812x | -62.31% |
| 2021-12-31 | $95.82 Million | $-47.94 Million | -0.500x | +26.70% |
| 2020-12-31 | $21.55 Million | $-14.71 Million | -0.683x | +55.48% |
| 2019-12-31 | $11.02 Million | $-16.89 Million | -1.533x | -104.45% |
| 2018-12-31 | $-458.00K | $-15.78 Million | 34.448x | +1586.17% |
| 2017-12-31 | $-11.27 Million | $-23.02 Million | 2.043x | +207.70% |
| 2016-12-31 | $13.57 Million | $-25.74 Million | -1.897x | -78.10% |
| 2015-12-31 | $28.20 Million | $-30.03 Million | -1.065x | -213.69% |
| 2014-12-31 | $54.21 Million | $-18.41 Million | -0.340x | -267.87% |
| 2013-12-31 | $-75.55 Million | $-15.28 Million | 0.202x | -67.41% |
| 2012-12-31 | $-19.71 Million | $-12.23 Million | 0.621x | -- |
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more